Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TFC-003

Phase 3Small molecule

TFC-003 is one of 45 small molecule programs targeting Glaucoma. It is currently in Phase 3.

2

Indications

2

Total Trials

1

Active Trials

44

Competitors

Pipeline

Status by Indication[3][1]

Indication

GlaucomaRecruiting

Ocular HypertensionActive, not recruiting

GlaucomaPhase 3

Recruiting

Ocular HypertensionPhase 2

Active, not recruiting

Competition

Competitive Landscape

187 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Alphagan

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Comparator: Pbo

Ocupress

Krytantek

LUMIGAN

Preservative-Free Tafluprost

TFC-003

Combigan

Duotrav

AAlcon Research

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Glaucoma

NCT07662759

Clinical

Trials by Indication[1]

Ocular Hypertension1 trial

A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Unknown status·KKukje Pharma·Phase 2·NCT06177678·60 enrolled

Glaucoma1 trial

A Prospective, Multicenter, Randomized, Investigator-Masked, Active-Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Recruiting·KKukje Pharma·Phase 3·NCT07662759·188 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TFC-003. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TFC-003 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TFC-003. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kukje Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKukje Pharma

Related News